Custom Antibody Services Market Size, Growth, Share by 2031
The custom antibody services market size is projected to reach US$ 1,216.35 million by 2031 from US$ 590.33 million in 2023. The market is expected to register a CAGR of 9.5% during 2023–2031. Technological advancements utilizing recombinant antibodies are likely to bring new trends in the custom antibody services market in the coming years.
Custom Antibody Services Market Analysis
The factors driving the custom antibody services market include government funding and support for research in antibody-related fields, coupled with the expansion into translational medicine. The growing emphasis on personalized medicine is fueling the demand for custom antibody solutions. Technological advancements using recombinant antibodies are boosting the growth of the custom antibody services market. Increasing demand for customized diagnostic and therapeutic treatments has boosted players to invest in product development and expansion strategies.
Custom Antibody Services Market Overview
Custom antibodies are essential to personalized therapies, as they can be designed to target specific molecular markers that are unique to an individual patient's disease. The custom antibody services market in the UK is anticipated to grow substantially owing to the growing prevalence of chronic diseases such as cancer and cardiovascular diseases. According to Cancer Research UK, ~360,000 people are diagnosed with cancer annually in the nation. The annual count of cancer diagnoses is projected to reach 500,000 by 2040. Antibodies have been demonstrated to prolong overall disease-free survival and delay disease progression in several cases. Custom antibody services are needed for the development of more targeted therapeutic antibody treatments to treat cancer more effectively.
Custom antibodies can help target specific tumor markers, improving the effectiveness and reducing side effects of cancer treatment. In September 2023, AMSBIO supplied a custom monoclonal antibody to researchers at the Technical University Dortmund, Germany, to unravel the role of EDI3 (a glycerophosphodiesterase enzyme involved in choline metabolism) in breast cancer development, its regulation by HER2 signaling, and its potential as a therapeutic target.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Custom Antibody Services Market: Strategic Insights
Custom Antibody Services Market
-
CAGR (2023 - 2031)
9.5%
-
Market Size 2023
US$ 590.33 Million
-
Market Size 2031
US$ 1,216.35 Million
Market Dynamics
GROWTH DRIVERS
- Rising Prevalence of Chronic Diseases
FUTURE TRENDS
- Rising Approvals of Biosimilars
OPPORTUNITIES
- Rise in Government Research and Development Activities
Key Players
- Thermo Fisher Scientific Inc
- Sino Biological Inc
- GenScript Biotech Corporation
- Biochain Incorporated
- R D Systems Inc
- Kaneka Eurogentec S A
- Fortis Life Sciences
- Precision Antibody
- Biocytogen Pharmaceuticals Beijing Co Ltd
- Abgenex
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Product Type
- Monoclonal
- Polyclonal hybridoma
- Recombinant antibody
Service Type
- Antibody Discovery and Development
- Antibody Production Services
Application
- Immunohistochemistry
- Western Blot & IP
- ELISA
- Fluorescence-activated cell sorting
- Mass Spectrometry
Disease Indication
- Oncology
- Infectious Diseases
- Immunology
- Cardiovascular Diseases
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Custom Antibody Services Market: Strategic Insights
-
CAGR (2023 - 2031)9.5% -
Market Size 2023
US$ 590.33 Million -
Market Size 2031
US$ 1,216.35 Million
Market Dynamics
- Rising Prevalence of Chronic Diseases
- Rising Approvals of Biosimilars
- Rise in Government Research and Development Activities
Key Players
- Thermo Fisher Scientific Inc
- Sino Biological Inc
- GenScript Biotech Corporation
- Biochain Incorporated
- R D Systems Inc
- Kaneka Eurogentec S A
- Fortis Life Sciences
- Precision Antibody
- Biocytogen Pharmaceuticals Beijing Co Ltd
- Abgenex
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Monoclonal
- Polyclonal hybridoma
- Recombinant antibody
- Antibody Discovery and Development
- Antibody Production Services
- Immunohistochemistry
- Western Blot & IP
- ELISA
- Fluorescence-activated cell sorting
- Mass Spectrometry
- Oncology
- Infectious Diseases
- Immunology
- Cardiovascular Diseases
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Custom Antibody Services Market Drivers and Opportunities
Rising Approvals of Biosimilars Favors Market Growth
The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to introduce safe and effective biosimilars to the market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.
A few recent approvals of biosimilar products are mentioned below:
Biosimilars Name | Approval Date | Reference Product |
Alymsys (bevacizumab-maly) | April 2022 | Avastin (bevacizumab) |
Cimerli (ranibizumab-eqrn) | August 2022 | Lucentis (ranibizumab) |
Fylnetra (pegfilgrastim-pbbk) | May 2022 | Neulasta (pegfilgrastim) |
Stimufend (pegfilgrastim-fpgk) | September 2022 | Neulasta (pegfilgrastim) |
Vegzelma (bevacizumab-adcd) | September 2022 | Avastin (bevacizumab) |
Idacio (adalimumab-aacf) | December 2022 | Humira (adalimumab) |
Biosimilars can reduce treatment costs and improve patient access to biologic therapies. In recent years, a vast range of biosimilars have been approved by the FDA. According to ScienceDirect.com, biosimilars can retain costs and expand the availability of monoclonal antibodies. Furthermore, in Europe, five rituximab biosimilars, six trastuzumab biosimilars, and eight bevacizumab biosimilars are available as anti-cancer drugs. Thus, the rising approvals of biosimilars fuel the growth of the custom antibody services market.
Rise in Government Research and Development Activities in Emerging and Developed Economies
Governments of various emerging countries are launching several research and development initiatives focusing on genomics and proteomic methods. For instance, The Proteomics Society, an organization in India, aims to promote the field of proteomics and the professional interests of the Proteomics Community in the country. The organization also helps facilitate research collaborations and workshops, driving the demand for custom antibody products. The Single Cell Proteomics Initiative of the US was established in 2022 from international laboratories that were proficient in performing Single-Cell Proteomics (SCP) workflows. The goal of the Single-Cell Initiative under the Biology and Disease-Driven Human Proteome Project unveiled in 2022 fostered the development and application of SCP methods and technologies. This initiative aims to accelerate knowledge exchange and resources within established and newly interested SCP researchers. The initiative organizes webinars, workshops, and symposia to showcase the modern advances and challenges in SCP, which are complemented by generating dedicated resources. Therefore, the rise in research and development initiatives by governments of various developing economies is expected to create lucrative opportunities for the growth of the custom antibody services market during the forecast period.
Custom Antibody Services Market Report Segmentation Analysis
Key segments that contributed to the derivation of the custom antibody services market analysis are product type, service type, application, source, disease indication, and end user.
- Based on product type, the custom antibody services market is categorized into monoclonal, polyclonal hybridoma, recombinant antibody, and others. The monoclonal segment held the largest share of the market in 2023.
- By service type, the custom antibody services market is segmented into antibody discovery and development, antibody production services, and others. The antibody discovery and development segment held the largest share of the market in 2023.
- Based on application, the market is categorized into immunohistochemistry, western blot & IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. The ELISA segment dominated the market in 2023.
- In terms of disease indication, the custom antibody services market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others. The oncology segment dominated the market in 2023.
- By source, the custom antibody services market is segmented into chicken, rabbits, rats, guinea pigs, mouse or humanized mice, and others. The mouse or humanized mice segment held the largest share of the market in 2023.
- In terms of end user, the custom antibody services market is segmented into the life science industry, pharmaceutical & biotech companies, academic & research institutes, and contract research organizations. The life science industry segment held the largest share of the market in 2023.
Custom Antibody Services Market Share Analysis by Geography
The geographic scope of the custom antibody services market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America held a significant share of the market in 2023. The growth of the market is driven by rising collaborations between government entities and market players to encourage the utilization of custom antibodies in clinical diagnostics. In addition, the acceptance and adoption of advanced technological solutions, increasing investments in drug discovery and development, extensive government support for clinical research, and an upsurge in research activities in clinical diagnostics are projected to accelerate the growth of the custom antibody services market in the region.
The growing number of cancer and genomic research programs run by universities in the US and Canada, increasing focus on developing antibody-based therapeutics, the presence of a large number of global players, and the burgeoning demand for high-quality research tools for data reproducibility are a few of the other factors contributing to the expansion of the market across North America.
Custom Antibody Services Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 590.33 Million |
Market Size by 2031 | US$ 1,216.35 Million |
Global CAGR (2023 - 2031) | 9.5% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Product Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Custom Antibody Services Market News and Recent Developments
The custom antibody services market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the custom antibody services market are listed below:
- Sino Biological, Inc., opened its new Center for Bioprocessing (C4B) in Houston, Texas, US, at Levit Green, adjacent to the world-renowned Texas Medical Center. Referred to as the C4B, the new center specializes in contract research services, including custom recombinant protein and recombinant antibody development and manufacture. The new center focuses on developing and producing research- and diagnostic-grade proteins and antibodies utilizing mammalian cells, which possess the unique machinery to yield natural, in vivo-like products with high bioactivity. (Source: Sino Biological, Inc., Press Release, October 2023)
- Fortis Life Sciences acquired the premium antibody company Bethyl Laboratories. Based in Texas, Bethyl Laboratories has a long history of offering its customers the highest quality primary and secondary antibodies, as well as other protein detection reagents. (Source: Fortis Life Sciences, Press Release, March 2021)
Custom Antibody Services Market Report Coverage and Deliverables
The “Custom Antibody Services Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Custom antibody services market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Custom antibody services market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Custom antibody services market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the custom antibody services market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Custom antibodies are essential to personalized therapies, as they can be designed to target specific molecular markers that are unique to an individual patient's disease. Custom antibody services are specialized services provided by companies to develop antibodies tailored to specific needs for research, diagnostic, and therapeutic purposes. These services include the entire process, from antigen design, immunization, and antibody production to purification and validation.
The factors driving the growth of the custom antibody services market include the increasing prevalence of chronic diseases and rising approvals of biosimilars. However, the high costs and complexities associated with antibody production using transgenic animals hampers the growth of the custom antibody services market.
The custom antibody services market majorly consists of the players, including Thermo Fisher Scientific Inc.; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc.; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody; Biocytogen Pharmaceuticals Beijing Co Ltd; and Abgenex.
The custom antibody services market was valued at US$ 590.33 million in 2023.
The custom antibody services market is expected to be valued at US$ 1,216.35 million by 2031.
The custom antibody services market, by product type, is segmented into monoclonal, polyclonal hybridoma, recombinant antibody, and others. In 2023, the monoclonal segment held the largest share of the market.
The List of Companies - Custom Antibody Services Market
- Thermo Fisher Scientific Inc.
- Sino Biological Inc.
- GenScript Biotech Corporation
- Biochain Incorporated
- R&D Systems, Inc.
- Kaneka Eurogentec S.A.
- Fortis Life Sciences
- Precision Antibody
- Biocytogen Pharmaceuticals Beijing Co Ltd
- Abgenex.